ARTICLE | Financial News
Immunex beats Street EPS
July 19, 2000 7:00 AM UTC
IMNX reported second quarter EPS of $0.08, beating by $0.01 the consensus $0.07 estimate. The company's Enbrel etanercept soluble TNF receptor to treat rheumatoid arthritis posted $155.1 million in sa...